ClinicalTrials.gg
RecruitingNCT02432092Updated Jun 22, 2026

Pediatric Cardiomyopathy Mutation Analysis

An observational study in Cardiomyopathies, Dilated Cardiomyopathy and Hypertrophic Cardiomyopathy, sponsored by Indiana University. Recruiting at 1 site in United States. Per ClinicalTrials.gov, last updated 2026-06-22.

Sponsored by Indiana University · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
300
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 231 studies in Cardiomyopathies with a site in United States — 56 open to participants now, 69 under way, 6 of them phase 3. Cardiomyopathies · United States.

Planned enrollment
38th of 97
300 · median 160
Started
2014
with 16 others
Observational
98 of 231
31 open now
Primary completion
2030-12
later than 59 of 67 live
Registered
109th of 231
by date

Among the 231 studies in Cardiomyopathies with a site in United States, this one is the 38th largest by planned enrollment of the 97 observational ones that give a count, is one of 17 that started in 2014, is one of 98 observational ones, reaches primary completion later than 59 of the 67 other live ones, and was the 109th registered.

Cardiomyopathies

556 studies on the registry are indexed under Cardiomyopathies; 153 are open to participants now.

Browse Cardiomyopathies studies →

Open to participants now

56 of the 231 studies in Cardiomyopathies with a site in United States are open now. Recruiting first, the newest first:

51 more — sign in →

All 56 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 116 Cardiomyopathies studies recruiting now, 70 (60%) set no upper age limit and 18 (16%) stop at 75 or younger; 35 take children under 18; 22 take healthy volunteers.

This study: all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 231 studies in Cardiomyopathies with a site in United States, or all of them as a file.
02

Study summary

The goal of this protocol is to obtain information from individuals with cardiomyopathy and from their families in order to elucidate the molecular genetics of this disorder. This will provide the basis for future genetic counseling as well as contribute to elucidating the biology of normal and abnormal cardiac function.

Read the detailed description

Cardiomyopathy is a genetically heterogeneous heart muscle disorder that results in ventricular dysfunction. While significant progress has been made in identifying the genetic basis of cardiomyopathy in adults, molecular diagnosis in children has proven more challenging and current algorithms do not incorporate mutation analysis in the clinical protocol. However, recent studies indicate that cardiomyopathy outcomes in children are origin specific, highlighting the importance of precise diagnosis. The goal of this study is to identify the genetic causes of pediatric cardiomyopathy. Rapid, comprehensive and cost-effective detection of genetic causes of cardiomyopathy will aid management and development of novel treatment strategies.

03

Conditions studied

  • Cardiomyopathies
  • Dilated Cardiomyopathy
  • Hypertrophic Cardiomyopathy
  • Restrictive Cardiomyopathy
  • Arrhythmogenic Right Ventricular Cardiomyopathy
  • Left Ventricular Non-compaction Cardiomyopathy

Keywords

  • Cardiomegaly
  • Cardiovascular Diseases
  • Heart Diseases
  • Systolic dysfunction
  • Diastolic dysfunction
  • Ventricular hypertrophy
  • Heart failure
04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Families affected by cardiomyopathy

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects with cardiomyopathy
  • Family members of subjects with cardiomyopathy

Exclusion criteria

Exclusion Criteria:

  • Subjects without cardiomyopathy
  • Family members of subjects without cardiomyopathy
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
300 participants (estimated)
Patient registry
No
Biospecimen retention
Samples with dna

Groups and cohorts

  • Affected

    participants with cardiomyopathy

  • Family Members of affected

    Family members of participants with cardiomyopathy (can be affected or unaffected)

06

What researchers measure

Primary outcomes

  1. Elucidate the molecular genetics of cardiomyopathy

    Time frame: 7 years

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Apr 2014, a primary completion of Dec 2030 and a completion of Dec 2030. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 28, 2015
First posted
May 1, 2015
Start
Apr 2014
Primary completionEst.
Dec 31, 2030
CompletionEst.
Dec 31, 2030
Last update
Jun 22, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 22, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02432092
Lead sponsor
Indiana University
Collaborators
American Heart Association
Responsible party
Stephanie Ware (Professor of Pediatrics and Medical and Molecular Genetics, Indiana University) — Principal investigator
First posted
May 1, 2015
Start date
Apr 2014
Primary completion
Dec 31, 2030 (estimated)
Completion
Dec 31, 2030 (estimated)
Last update
Jun 22, 2026

Study contacts

Sarah Murphy, MPH
Contact
bankssk@iu.edu
(317) 278-3026
Stephanie Ware, MD, PhD
Contact
stware@iu.edu
(317) 278-2807
Stephanie Ware, MD, PhD
principal investigator · IU School of Medicine

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion